Impact of pre-existing drug resistance on risk of virological failure in South Africa | Zendy

Jonathan Z. Li | Zendy; Natalia Stella-Ascariz | Zendy; Manish C. Choudhary | Zendy; Aneela Javed | Zendy; Katherine Rodríguez | Zendy; Heather Ribaudo | Zendy; MahomedYunus S. Moosa | Zendy; Jay Brijkumar | Zendy; Selvan Pillay | Zendy; Henry Sunpath | Zendy; Marc Noguera-Julián | Zendy; Roger Paredes | Zendy; Brent A. Johnson | Zendy; Johnathan A. Edwards | Zendy; Vincent C. Marconi | Zendy; Daniel R. Kuritzkes | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Impact of pre-existing drug resistance on risk of virological failure in South Africa

Author(s) -

Jonathan Z. Li,

Natalia Stella-Ascariz,

Manish C. Choudhary,

Aneela Javed,

Katherine Rodríguez,

Heather Ribaudo,

MahomedYunus S. Moosa,

Jay Brijkumar,

Selvan Pillay,

Henry Sunpath,

Marc Noguera-Julián,

Roger Paredes,

Brent A. Johnson,

Johnathan A. Edwards,

Vincent C. Marconi,

Daniel R. Kuritzkes

Publication year - 2021

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkab062

Subject(s) - efavirenz , emtricitabine , medicine , cohort , drug resistance , population , proportional hazards model , human immunodeficiency virus (hiv) , viral load , tenofovir , drug , cohort study , antiretroviral therapy , oncology , virology , pharmacology , biology , genetics , environmental health

There is conflicting evidence on the impact of pre-existing HIV drug resistance mutations (DRMs) in patients infected with non-B subtype virus.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research